IP Library Granted Patent US 10,568,990
Granted Patent B2
US 10,568,990 · App. 14/938,173 · Granted Feb 25, 2020

Cell repopulated collagen matrix for soft tissue repair and regeneration

Inventors: Reginald L. Stilwell (Parker, CO); Brent Atkinson (Littleton, CO); Yaling Shi (Larkspur, CO); Brian Dittman (Lenexa, KS)
Assignee: ALLOSOURCE
A61L27/60A61K35/28A61L27/24A61L27/362A61L27/3604A61L27/3641A61L27/3687A61L27/3691A61L27/3834A61L27/54C12N5/0667A61L2300/252A61L2300/414A61L2300/426A61L2300/64A61L2430/34A61L2430/40C12N2533/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,568,990
App. No.
14/938,173
Granted
Feb 25, 2020
Kind
B2
Abstract

The present invention provides compositions for treating soft tissue injuries comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix. Methods of making and using compositions comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix are also provided.

Claims (31)

1. A composition for treating a soft tissue injury in a subject, the composition comprising:

a flowable acellular dermal collagen matrix, the flowable acellular dermal collagen matrix comprising cryofractured and thawed acellular dermal tissue having a disrupted extracellular matrix collagen or macrostructure and a partially disrupted collagen microfibrillar architecture; and

mesenchymal stem cells adhered to the flowable acellular dermal collagen matrix, wherein the mesenchymal stem cells are derived from a tissue processed to form a cell suspension comprising mesenchymal stem cells and non-mesenchymal stem cells that is seeded onto the collagen matrix, and wherein the mesenchymal stem cells are not cultured ex vivo after formation of the cell suspension and prior to seeding of the cell suspension on the collagen matrix.

2. The composition of claim 1 , wherein the flowable acellular dermal collagen matrix is decellularized dermis.

3. The composition of claim 1 , wherein the flowable acellular dermal collagen matrix is dermis from which the epidermis layer has been removed.

4. The composition of claim 1 , wherein the collagen matrix is obtained from a human, a porcine, a bovine, or an equine donor.

5. The composition of claim 1 , wherein the tissue that is processed to form the cell suspension is selected from adipose tissue, muscle tissue, birth tissue, skin tissue, bone tissue, or bone marrow tissue.

6. The composition of claim 1 , wherein the collagen matrix and the tissue that is processed to form the cell suspension are from the same donor.

7. The composition of claim 1 , wherein the collagen matrix and the tissue that is processed to form the cell suspension are from different donors.

8. The composition of claim 1 , wherein the mesenchymal stem cells seeded on the collagen matrix express one or more positive mesenchymal stem cell markers.

9. The composition of claim 8 , wherein the mesenchymal stem cells seeded on the collagen matrix do not express one or more negative mesenchymal stem cell markers.

10. The composition of claim 1 , wherein the tissue that is digested to form the cell suspension is adipose tissue.

11. The composition of claim 1 , wherein the flowable acellular dermal collagen matrix and the tissue that is digested to form the cell suspension are from a human donor.

12. The composition of claim 1 , wherein the flowable acellular dermal collagen matrix and the tissue that is digested to form the cell suspension are from a single human donor.

13. The composition of claim 1 , wherein the flowable acellular dermal collagen matrix comprises cryofractured and thawed acellular dermal tissue.

14. A method of treating a soft tissue injury in a subject, the method comprising contacting the soft tissue injury with the composition of claim 1 .

15. The method of claim 14 , wherein the soft tissue injury is an injury to a tendon tissue, a ligament tissue, a meniscus tissue, a muscle tissue, a skin tissue, a bladder tissue, or a dermal tissue.

16. The method of claim 14 , wherein the soft tissue injury is a surgical wound, a trauma wound, a chronic wound, an acute wound, a deep channel wound, an exsanguinating site, or a burn.

17. The method of claim 14 , wherein the composition is administered topically.

18. The method of claim 14 , wherein the composition is administered by surgical implantation.

19. A method of making a composition for treating a soft tissue injury, the method comprising:

(a) digesting a tissue to form a cell suspension comprising mesenchymal stem cells and non-mesenchymal stem cells;

(b) seeding the cell suspension of step (a) onto a flowable acellular dermal collagen matrix, wherein the flowable acellular dermal collagen matrix comprises cryofractured and thawed acellular dermal tissue having a disrupted extracellular matrix collagen or macrostructure and a partially disrupted collagen microfibrillar architecture;

(c) incubating the flowable acellular dermal collagen matrix seeded with the cell suspension under conditions suitable for adhering the mesenchymal stem cells to the collagen matrix; and

(d) removing the non-adherent cells from the flowable acellular dermal collagen matrix.

20. The method of claim 19 , wherein the flowable acellular dermal collagen matrix is obtained from a human, a porcine, a bovine, or an equine donor.

21. The method of claim 19 , wherein the tissue that is digested to form the cell suspension is selected from adipose tissue, muscle tissue, birth tissue, skin tissue, bone tissue, or bone marrow tissue.

22. The method of claim 19 , wherein the flowable acellular dermal collagen matrix and the tissue that is digested to form the cell suspension are from a single donor.

23. The method of claim 19 , wherein the tissue that is digested to form the cell suspension is adipose tissue.

24. The method of claim 19 , wherein the flowable acellular dermal collagen matrix and the tissue that is digested to form the cell suspension are from a human donor.

25. The method of claim 19 , wherein the flowable acellular dermal collagen matrix and the tissue that is digested to form the cell suspension are from a single human donor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: SHI, YALING; DITTMAN, BRIAN; ATKINSON, BRENT; STILLWELL, REGINALD
To: ALLOSOURCE
Reel/Frame 038996/0565 →
Continuity (3)
Continuation 14207220 · Mar 12, 2014
Provisional Application 61790412 · Mar 15, 2013
Related Publication 20160263284A1 · Sep 15, 2016
Cited By (1)
US 12,551,509